What’s New in MCS

March 2014

Simon Maltais, MD, PhD
Assistant Professor of Surgery-Assistant Professor of Medicine (Cardiology)
Surgical Director, Heart Transplantation and Mechanical Support Devices
Vanderbilt Heart and Vascular Institute
Nashville, TN, USA
simon.maltais@Vanderbilt.Edu

Articles:

ASAIO Journal (March/April 2014 Issue):

Thrombus Formation Patterns in the HeartMate II Ventricular Assist Device: Clinical Observations Can Be Predicted by Numerical Simulations
Chiu, Wei-Che; Slepian, Marvin J.; Bluestein, Danny

Ventricular Assist Device Thrombosis Following Recovery of Left Ventricular Function
Sifain, Andrew R.; Schwarz, Karl Q.; Hallinan, William; More

**De Novo Aortic Insufficiency During Long-Term Support on a Left Ventricular Assist Device: A Systematic Review and Meta-Analysis
Deo, Salil V.; Sharma, Vikas; Cho, Yang Hyun; More

*Outcomes and Predictors of Early Mortality After Continuous-Flow Left Ventricular Assist Device Implantation as a Bridge to Transplantation
Sabashnikov, Anton; Mohite, Prashant N.; Zych, Bartlomiej; More

End-Organ Recovery Is Key to Success for Extracorporeal Membrane Oxygenation as a Bridge to Implantable Left Ventricular Assist Device
Durinka, Joel B.; Bogar, Linda J.; Hirose, Hitoshi; More

Early Feasibility Testing and Engineering Development of the Transapical Approach for the HeartWare MVAD Ventricular Assist System
Tamez, Daniel; LaRose, Jeffrey A.; Shambaugh, Charles; More

Noninvasive Arterial Blood Pressure Waveforms in Patients with Continuous-Flow Left Ventricular Assist Devices
Martina, Jerson R.; Westerhof, Berend E.; de Jonge, Nicolaas; More

Anticoagulation Therapy Trends in Children Supported by Ventricular Assist Devices: A Multi-Institutional Study
Moffett, Brady S.; Cabrera, Antonio G.; Teruya, Jun; More

Implantation of the HeartMate II and HeartWare Left Ventricular Assist Devices in Patients With Duchenne Muscular Dystrophy: Lessons Learned From the First Applications
Ryan, Thomas D.; Jefferies, John L.; Sawnani, Hemant; More
A Mock Circulatory System to Assess the Performance of Continuous-Flow Left Ventricular Assist Devices (LVADs): Does Axial Flow Unload Better Than Centrifugal LVAD?
Sénage, Thomas; Février, Dorothée; Michel, Magali; More
ASAIO Journal. 60(2):140-147, March/April 2014.

Elevation of Procalcitonin After Implantation of an Interventional Lung Assist Device in Critically Ill Patients
Kott, Matthias; Bewig, Burkhard; Zick, Günther; More

Pharmacist-Managed International Normalized Ratio Patient Self-Testing Is Associated with Increased Time in Therapeutic Range in Patients with Left Ventricular Assist Devices at an...
Bishop, Martin A.; Streiff, Michael B.; Ensor, Christopher R.; More

Sex-Specific Outcomes in Patients Receiving Continuous-Flow Left Ventricular Devices as a Bridge to Transplantation or Destination Therapy
Tsiouris, Athanasios; Morgan, Jeffrey A.; Nemeh, Hassan W.; More

Do Not Touch the Sternum—Thoracotomy Incisions for HVAD Implantation
Deuse, Tobias; Reichenspurner, Hermann

Do Axial-Flow LVADs Unload Better than Centrifugal-Flow LVADs?
Giridharan, Guruprasad A.; Koenig, Steven C.; Slaughter, Mark S.

Acquired von Willebrand Disease During CentriMag Support Is Associated with High Prevalence of Bleeding During Support and After Transition to Heart Replacement Therapy
Morrison, Kerry A.; Jorde, Ulrich P.; Garan, Arthur R.; More

Home Discharge and Out-of-Hospital Follow-Up of Total Artificial Heart Patients Supported by a Portable Driver System
El Banayosy, Aly; Kizner, Lukacz; Arusoglu, Latif; More

Journal of Thoracic and Cardiovascular Surgery (March 2014 Issue):

Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery

Journal of the American College of Cardiology:

**Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support: An Analysis of More Than 900 HeartMate II Outpatients
Journal of the American College of Cardiology, Volume 63, Issue 9, 11 March 2014, Pages 880-888

Circulation: Heart Failure:

Prevalence, Significance, and Management of Aortic Insufficiency in Continuous Flow Left Ventricular Assist Device Recipients
Ulrich P. Jorde
Circ Heart Fail. 2014;7:310-319, published online before print January 10 2014, doi:10.1161/CIRCHEARTFAILURE.113.000878

Outcomes of Patients With Peripartum Cardiomyopathy Who Received Mechanical Circulatory Support: Data From the Interagency Registry for Mechanically Assisted Circulatory Support
**De Novo Aortic Insufficiency During Long-Term Support on a Left Ventricular Assist Device: A Systematic Review and Meta-Analysis**

Deo, Salil V.; Sharma, Vikas; Cho, Yang Hyun; More

Aortic insufficiency (AI) may occur while supported on a left ventricular assist device (LVAD). The Mayo group conducted a systematic review to determine the incidence, predictors, and consequences of AI during LVAD support.

This study included a MEDLINE search for original studies presenting clinical data regarding patients who developed AI during LVAD implant. Seven observational studies (657 patients) were selected for review. The incidence of AI was 25% (11-42%) (Support period: 412 ± 281 days). AI increased by 4% (1-6%) per month of support (p < 0.01). AI-positive patients were older at implant (weighted mean difference, 7.7 [4.3; 11.1]; p < 0.01). Female sex (0.002 ± 0.001; p = 0.01) and smaller body surface area (-0.003 ± 0.001 per m; p < 0.01) correlated with progressive AI. Destination therapy patients (odds ratio [OR], 5.3 [1.2, 24]; p = 0.02) and those with Cf-LVAD pumps were likely to develop AI (hazard ratio [HR], 2.2 [1.2, 3.8]; p < 0.01). A closed aortic valve was associated with AI (OR, 4.7 [1.9, 11.8]; p < 0.01). Survival was comparable in both cohorts (HR, 1.5 [0.81, 2.8]; p = 0.2). A significant number of patients develop de novo AI during LVAD support. Advanced age, longer support duration, continuous-flow pumps, and a closed aortic valve are associated with AI.

**Analysis:**

This study represents a large and systematic review of the incidence, importance, and predicting factors of AI development after LVAD implantation. Several controversies and misconceptions exist when evaluating the importance of AI for patients undergoing LVAD implantation. This study reaffirms the need to careful assessment of AI during implant and emphasizes patient and clinical factors to consider when making a decision to address AI. With the increased importance of destination therapy, further detailed studies regarding this specific aspect will be crucial to develop appropriate and clear guidelines for this complex patient population.

**Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support: An Analysis of More Than 900 HeartMate II Outpatients**

Journal of the American College of Cardiology, Volume 63, Issue 9, 11 March 2014, Pages 880-888

This study sought to determine the pre-operative risk factors related to late bleeding, stroke, and pump thrombosis in patients with HeartMate II (HMII) left ventricular assist devices (LVADs). From the HMII Investigators, this study represents a large cohort of patients and addresses an important topic.

This was a retrospective analysis of prospectively collected data. A total of 956 patients with advanced heart failure discharged from the hospital where analyzed. Authors sought to evaluate preoperative risk factors for bleeding and stroke in the outpatient setting.

Main findings are that adverse event rates for post-discharge bleeding (0.67 events/patient-year) were higher than those for hemorrhagic stroke (0.05), ischemic stroke (0.04), and pump thrombosis (0.03).
Older age (>65 years) (hazard ratio [HR]: 1.31), lower pre-operative hematocrit (≤31%) (HR: 1.31), ischemic etiology (HR: 1.35), and female (HR: 1.45) were statistically significant multivariable risk factors for bleeding. Female (HR: 1.92) and 65 years of age and younger (HR: 1.94) were multivariable risk factors for hemorrhagic stroke, whereas female (HR: 1.84) and history of diabetes (HR: 1.99) were risk factors for ischemic stroke. Female (HR: 1.90) and higher body mass index (HR: 1.71/10 kg/m(2) increase) were also multivariable risk factors for pump thrombosis.

**Analysis**

This study is important as it relates to a large number of patients. Understanding clinical factors involved in stroke and bleeding is critical for the progress of our field. Despite its lack of granularity, this study starts to indentify preoperative factors associated with common adverse events, and how it relates to patient and disease conditions. Further studies with large collaborative cohort outside of published pivotal trials are however needed to truly understand conditions, but most importantly, post discharge factors (hypertension, anticoagulation, pump speed, etc) that are truly important for adverse pump-related events.

Disclosure statement: the author is a consultant for Heartware and Thoratec, but does not have any associations or relationship with industry that might pose a conflict of interest with this submitted work.